Your session is about to expire
← Back to Search
Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer (RESTORE Trial)
N/A
Waitlist Available
Led By Dianne M Shumay
Research Sponsored by Blue Note Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing two special apps designed to help cancer patients reduce anxiety and improve their overall health. The study focuses on patients with stage I-III cancer who are undergoing or have recently undergone treatments like chemotherapy or radiation. The apps will be used for a few months along with their usual medical care.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Symptoms of anxiety
Secondary study objectives
Acceptability of each digital product
Benefit Finding
Cancer-related symptoms of anxiety (thought intrusions)
+12 moreOther study objectives
Healthcare utilization
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Active Control
Group I: Cerena™Active Control1 Intervention
Cerena™ is a completely digital therapeutic intervention.
Group II: Attune™Active Control1 Intervention
Attune™ is a completely digital therapeutic intervention.
Find a Location
Who is running the clinical trial?
CurebaseUNKNOWN
2 Previous Clinical Trials
1,415 Total Patients Enrolled
Curebase Inc.Industry Sponsor
6 Previous Clinical Trials
3,248 Total Patients Enrolled
Blue Note TherapeuticsLead Sponsor
6 Previous Clinical Trials
429 Total Patients Enrolled
Dianne M ShumayPrincipal InvestigatorBlue Note Therapeutics